

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 24, 2020

OptimizeRx Corporation  
(Exact name of registrant as specified in its charter)

<u>Nevada</u> (State or other jurisdiction of incorporation)	<u>001-38543</u> (Commission File Number)	<u>26-1265381</u> (I.R.S. Employer Identification No.)
<u>400 Water Street, Suite 200, Rochester, MI</u> (Address of principal executive offices)		<u>48307</u> (Zip Code)

Registrant's telephone number, including area code: 248.651.6568

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading symbol</u>	<u>Name of each exchange on which registered</u>
Common Stock	OPRX	Nasdaq Capital Market

## **SECTION 8 – Other Events**

### **Item 8.01 Other Events**

On August 24, 2020, we issued a press release announcing our invitation to present at the LD 500 virtual institutional investor conference being held on September 1-4, 2020.. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 8.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

## **SECTION 9 – Financial Statements and Exhibits**

### **Item 9.01 Financial Statements and Exhibits**

99.1 [Press release, dated August 24, 2020](#)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**OptimizeRx Corporation**

/s/ Douglas Baker

Douglas Baker  
Chief Financial Officer

Date August 24, 2020



### **OptimizeRx to Present at the LD 500 Virtual Investor Conference on Sept. 3, 2020**

**ROCHESTER, Mich. – August 24, 2020** – OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, providers and patients, has been invited to present at the LD 500 virtual institutional investor conference being held on September 1-4, 2020.

OptimizeRx CEO, William Febbo, is scheduled to present on Thursday, September 3, at 12:20 p.m. Eastern time and participate in virtual one-on-one meetings with institutional analysts and investors throughout the day.

The presentation will be webcast live and available for replay here and via the investor relations section of the company's website at [www.optimizerx.com](http://www.optimizerx.com).

Management will discuss how OptimizeRx's growing digital point-of-care solutions have evolved into 'must-haves' for life science companies looking to improve essential communications with physicians and patients.

They will also discuss the company's recent expansion of its digital health platform from ambulatory and acute care to retail pharmacy, which includes access to a new nationwide network of 10,000 FDA-cleared self-screening Smart Health Stations.

The LD 500 is one of the nation's largest independent conferences for micro-cap companies, with over 300 names presenting. The conference will also feature variety of speakers and panelists discussing topics of interest to investors and issuers.

To schedule a virtual one-on-one meeting with OptimizeRx, you may submit your request to register for the conference here or contact David Scher at [david@ldmicro.com](mailto:david@ldmicro.com) or visit [www.ldmicro.com/events](http://www.ldmicro.com/events).

View OptimizeRx's LD Micro profile here: [www.ldmicro.com/profile/OPRX](http://www.ldmicro.com/profile/OPRX)

Profiles powered by LD Micro and news distribution compliments of Accesswire

## **About OptimizeRx**

OptimizeRx Corporation (NASDAQ: OPRX) is a digital health company that facilitates communication at point-of-care among all stakeholders in healthcare. Primarily focused on life science and payer clients, its suite of digital and mobile SaaS-based solutions enables affordability, patient adherence and care management. OptimizeRx's network reaches more than 60% of U.S. ambulatory providers, delivering therapeutic support on specialty medications and patient financial assistance directly within a provider's workflow through leading electronic health platforms. OptimizeRx's fully integrated platform supports the real-time exchange of information, improving provider knowledge and patient engagement, and ultimately leading to healthier outcomes.

For more information, follow the company on Twitter, LinkedIn or visit [www.optimizerx.com](http://www.optimizerx.com).

## **Important Cautions Regarding Forward Looking Statements**

This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

## **OptimizeRx Contact**

Doug Baker, CFO  
Tel (248) 651-6568 (x807)  
[dbaker@optimizerx.com](mailto:dbaker@optimizerx.com)

## **Media Relations Contact**

Maira Alejandra, Media Relations Manager  
Tel (754) 245-7070  
[malejandra@optimizerx.com](mailto:malejandra@optimizerx.com)

## **Investor Relations Contact**

Ron Both, CMA  
Tel (949) 432-7557  
[opr@cma.team](mailto:opr@cma.team)